Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23513252 | 0.94 | SMN1; SMN2 (0.51) | SMN1; SMN2PIN1ALOX5LMNANPC1 | |
| SCHEMBL22144166 | 0.93 | PIN1 (0.50) | SMN1; SMN2PIN1ALOX5LMNANPC1 | |
| SCHEMBL3211799 | 0.93 | PIN1 (0.52) | SMN1; SMN2PIN1ALOX5LMNANPC1 | |
| SCHEMBL3211795 | 0.90 | PIN1 (0.50) | SMN1; SMN2PIN1ALOX5LMNANPC1 | |
| SCHEMBL3213534 | 0.89 | ALDH1A1 (0.55) | SMN1; SMN2PIN1ALOX5LMNANPC1 | |
| SCHEMBL5941081 | 0.89 | PIN1 (0.56) | SMN1; SMN2PIN1ALOX5LMNANPC1 | |
| SCHEMBL4108739 | 0.89 | LMNA (0.53) | SMN1; SMN2PIN1ALOX5LMNANPC1 | |
| SCHEMBL13086854 | 0.89 | SMN1; SMN2 (0.51) | SMN1; SMN2PIN1ALOX5LMNANPC1 | |
| SCHEMBL9686760 | 0.88 | PIN1 (0.53) | SMN1; SMN2PIN1ALOX5LMNANPC1 | |
| SCHEMBL4433228 | 0.87 | PIN1 (0.52) | SMN1; SMN2PIN1ALOX5LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| EP-4216951-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022066646-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-9856261-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856261-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3026052-A9 | PREPARATION OF DEUTERATED PIPERIDINE INHIBITORS OF JANUS KINASE 3 | Auspex Pharmaceuticals, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-3026052-A9 | PREPARATION OF DEUTERATED PIPERIDINE INHIBITORS OF JANUS KINASE 3 | Auspex Pharmaceuticals, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20130040974-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8299084-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299084-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299084-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2421867-A2 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | Auspex Pharmaceuticals, Llc (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20100291026-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100291026-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100291026-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2010123919-A2 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | AUSPEX PHARMACEUTICALS, LLC (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123919-A2 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | AUSPEX PHARMACEUTICALS, LLC (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357277-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | SMN1; SMN2 4519/4885PIN1 309/4885ALOX5 4218/4885 |
| US-20130040974-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | JAK2, JAK3, PAK3 | SMN1; SMN2 4257/4885PIN1 1089/4885ALOX5 1566/4885 |
| US-20100291026-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | JAK2, JAK3, PAK3 | SMN1; SMN2 4257/4885PIN1 1089/4885ALOX5 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.